The MyRose Pregnancy Registry

Join the registry to help pregnant women, researchers, and healthcare providers learn about the safety of using MYFEMBREE® (relugolix CT) for the treatment of heavy menstrual bleeding due to uterine fibroids or moderate to severe pain related to endometriosis in premenopausal women. This study is a pregnancy registry that collects health information from women who take prescription medicines when they are pregnant.

Would you like to participate?

Contact the Registry today

Am I eligible?

You may be eligible if you are:

  • A resident of the United States
  • A pregnant woman who has:
    • Been diagnosed with uterine fibroids or endometriosis; or
    • Taken MYFEMBREE® (relugolix CT) during pregnancy or just prior to pregnancy (within 13 days prior to conception)

How do I participate?

For more information on the MyRose Pregnancy Registry, or to learn more about your eligibility to participate, you can:

Contact Request Form icon

Complete the Contact Request Form here and a registry staff member will contact you

Email the registry team with your contact information at:

Telephone icon

Call the registry team toll-free at
1-877-390-2723
(hours of operation 8.30am - 5.00pm EST Monday-Friday)

Future pregnant women with uterine fibroids or endometriosis, their healthcare providers, and researchers can benefit from the information you provide to the registry.

If you are eligible and would like to participate, you will be asked to:

  1. Provide your consent (a requirement for participation in any research study)
  2. Give the registry permission to contact your healthcare provider(s) to collect information for the study

You and your healthcare provider(s) will give information to the registry about your pregnancy and your infant’s health up to 1 year of age. This information can be provided by completing paper forms, via the website portal or via short phone interviews with one of the registry staff members. Only information normally documented in your medical record will be collected.

If you participate, there will be:

  • No extra doctor’s visits or additional testing
  • No changes to your existing healthcare provider(s) or care
  • No changes to your current treatment

You and your healthcare provider(s) will receive compensation for providing data to the registry.

If you are eligible and would like to participate, you will be asked to provide information to the registry at enrollment and periodically throughout your pregnancy:

  • At enrollment, you will be asked to provide basic information about yourself (e.g., race, ethnicity, education, height, and weight) and information about your history of uterine fibroids or endometriosis.
  • You will be paid $50.00 for your participation in the Registry. You will be paid $25 after the registry confirms with your healthcare provider that you are eligible and another $25 when your infant reaches 1 year and/or when your infant’s healthcare provider communicates to the Registry Coordinating Center they have no further information available.

MYFEMBREE® (relugolix CT) is a prescription medicine made by Myovant Sciences GmbH that is approved to treat uterine fibroids and/or endometriosis in premenopausal women.

It is for the:

  • Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in adult premenopausal women, or
  • Management of moderate-to-severe pain associated with endometriosis in premenopausal women.

Would you like to participate?

Enroll in the Registry